Pentagamavunone-1 or PGV-1 has been reported to eliminate cancer cell progression in the breast, blood, and colon. The current approach evaluates the antiproliferative and its cellular activity of PGV-1 against hepatocellular carcinoma cells (HCC). We used the HepG2 cells as an in vitro model for HCC, and PGV-1 was tested for the effect on cell viability, cell cycle modulation, senescence induction, ROS generation, and cell migration. Further assessment of PGV-1 to prevent liver carcinogenesis was also employed on 1,2-dimethylhydrazine (DMH)-induced rats. PGV-1 irreversibly inhibited cell proliferation markedly through mitotic arrest and cellular senescence. The ROS production was enhanced during earlier hours of incubation with the compound. Later, PGV-1 significantly delayed the HepG2 cell migration and invasion. In addition, PGV-1 prevented steatohepatitis upon DMH administration and drastically reduced the Ki-67 expression in DMH-induced rat liver indicating its ability to suppress aberrant liver cell proliferation. These findings again support the evidence of the prospect of PGV-1 being pharmaceutically developed further as a candidate for cancer therapy with a specific target on mitosis.
Key words: curcumin analog, liver cancer, mitotic arrest, anti-migration, hepatoprotective
|
